je.st
news
Tag: express
First Hitachi-built Intercity Express Train arrives in UK
2017-06-20 01:00:00| Railway Technology
The first Intercity Express Train built at Hitachi's factory in Japan has arrived in Southampton port, UK.
Tags: uk
express
train
arrives
FEDERAL EXPRESS 2007 HOLIDAY SCHEDULE
2017-06-19 11:55:17| Bird Shippers of America
Jan. 1 - FedEx Reopens Jan. 2 Jan. 15 - Not observed by FedEx Feb. 19 - Not observed by FedEx May 28 - FedEx Reopens May 29 July 4 - FedEx Reopens July 5th. That July 4th is on...
Tags: express
holiday
federal
schedule
FEDERAL EXPRESS UPDATE
2017-06-19 11:55:17| Bird Shippers of America
December 13, 2006 We received the following updates on Federal Express "Lives" service through the Post Office. Because we have temperatures below 85 degrees now, the restrictions for the following areas have been lifted; Birmingham AL (BHM) Zip Codes: 350-352,...
Tags: update
express
federal
federal express
FEDERAL EXPRESS AND POST OFFICE CONTRACTUAL AGREE ON CARRING LIVES
2017-06-19 11:55:17| Bird Shippers of America
Federal Express and the US post office have reached a contractual agreement on carrying "LIVES". Starting on September 25, Federal Express has taken over the routs previously served by Kitty Hawk (see below for a listing). This is a contractual...
Tags: post
office
express
agree
KEYTRUDA (pembrolizumab) Approved as First Anti-PD-1 Therapy in Japan for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express High Levels of PD-L1
2016-12-19 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, has been approved in Japan for the treatment of certain patients with PD-L1-positive unresectable advanced/recurrent non-small cell lung cancer (NSCLC) in the first- and second-line treatment settings at a fixed dose of 200 mg every three weeks. MSD will manufacture and market KEYTRUDA in Japan and will promote it with Taiho Pharmaceutical Co., Ltd. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »